What You Need to Know About Orforglipron t2diabetesnetwork Apr 1 4 min read Updated: May 19 Written by Clare Koning, RN, PhD T2D Network | April 2026 | 6 min read Key Highlights Orforglipron is a once-daily GLP-1 pill: no injections, no food or water timing restrictions Phase 3 trials showed A1C reductions of 1.3%1.6% and meaningful weight loss In a head-to-head trial published in The Lancet , it outperformed oral semaglutide on every key endpoint Regulatory submissions are underway in 40+ countries: U.S
Liu C, Li B, Yan Q, Niu S, Zhao Y, Xiong C, et al
A 12-week trial showed that subjects receiving 1 mg per day of AOD 9604 lost an average of 2.6 kilograms compared to 0.8 kilograms in the placebo group
Gip loi b hc sc t thm sm, bt sng ln da t gc t bo, lm u mu da
Anaphylaxis has been reported
However, a recent systematic review by Losurdo et al